Evaxion A/S (NASDAQ: EVAX) completed the one-year extension of its phase 2 trial for personalized cancer vaccine EVX-01, with the last patient completing their final physician visit. The company expects to present three-year clinical data in the second half of 2026.

The trial evaluated EVX-01 as a treatment for advanced melanoma. During the first two years, patients received EVX-01 in combination with Merck's Keytruda. In the third year, patients received EVX-01 as monotherapy.

Data from the first two years showed an Objective Response Rate of 75%, with 12 out of 16 patients having objective clinical responses and four patients achieving complete response. At two-year follow-up, 92% of patients remained responsive with no observed relapses.

The trial results indicated that 54% of patients experienced deepened responses during treatment, progressing from stable disease or partial response to partial or complete response. Tumor reduction in target lesions occurred in 15 out of 16 enrolled patients.

EVX-01 induced immune responses in all patients, with 81% of targeted neoantigens generating specific T-cell responses. The treatment was confirmed to be well-tolerated.

"We are pleased to have carried through the extension of the trial as planned and are looking forward to collecting, analysing and presenting the data," said Birgitte Rønø, chief scientific officer of Evaxion.

EVX-01 is designed using Evaxion's AI-Immunology platform. The Copenhagen-based company develops vaccines using artificial intelligence technology.